Garry Neil, M.D. is Corporate Vice President, Corporate Office of Science and Technology (COSAT), Johnson & Johnson. In this role, Garry leads a team that catalyzes sustained growth for Johnson & Johnson by identifying and launching emerging technologies that underpin the creation of future businesses.

Garry has broad experience in the science, medicine and pharmaceutical development. He has held a number of senior positions within J&J, most recently Group President, Johnson and Johnson Pharmaceutical Research and Development where he was responsible for maximizing existing strengths and leveraging collective resources to bring innovative new molecular entities (NMEs) to market quickly and cost effectively. Through a number of new initiatives he helped transform J&J's pharmaceutical R&D to a much more capable and productive organization and helped recruit a number of top scientists. Under his leadership a number of important new medicines for the treatment of cancer, anemia, infections, central nervous system and psychiatric disorders, pain, and genitourinary and gastrointestinal diseases, gained initial or new and/or expanded indication approvals.

Garry joined J&J in 2002 as Senior Vice President of Drug Development at Johnson & Johnson Pharmaceutical Research and Development (J&JPRD). In 2005, Garry became President of J&JPRD, and in 2006, was promoted to Group President. Before joining J&JPRD, he held senior-level positions with Astra Merck Inc., Astra Pharmaceuticals, Astra Zeneca and Merck KGaA. He has also held a number of academic posts at a number of academic institutes including the Ludwig Institute for Cancer Research, the University of Toronto, the University of Iowa, College of Medicine and the University of Pennsylvania (adjunct).

Any questions concerning workshops sponsored by ORSP, please contact  Mary Feldenkreiss at felden@orsp.rutgers.edu or (732) 932-0150 x3015.

Return to ORSP Home